• Diana Paredes-Ruiz, Daniel Martin-Iglesias, and Guillermo Ruiz-Irastorza.
• Autoimmune Diseases Research Unit, Department of Internal Medicine, Biobizkaia Health Research Institute, Hospital Universitario Cruces, Spain.
• Med Clin (Barc). 2024 Aug 1; 163 Suppl 1: S22S30S22-S30.

AbstractThrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic lupus erythematosus or other systemic autoimmune diseases and the presence of risk factors for cardiovascular disease and bleeding. Anticoagulation with vitamin K antagonists (VKA) remains the cornerstone of therapy for thrombotic APS. As platelets play a central role in APS, low-dose aspirin is the first option for primary thromboprophylaxis in asymptomatic aPL carriers, and also plays a role as combination therapy with VKAs in arterial thrombosis. Treatment with direct oral anticoagulants (DOACs) could be considered in certain low-risk situations, although they are not recommended in patients with arterial thrombosis or triple positive aPL. Adjuvant therapies such as hydroxychloroquine and statins may be useful in complex settings such as thrombotic recurrences or high risk of bleeding. In this article, we review the evidence and the recommendations of the guidelines for the treatment of APS, and provide a critical and practical approach of its management from our clinical perspective.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

34 keywords...

hide…